Y-mAbs Therapeutics, Inc. (YMAB) News

Y-mAbs Therapeutics, Inc. (YMAB): $9.56

0.04 (+0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter YMAB News Items

YMAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

YMAB News Highlights

  • For YMAB, its 30 day story count is now at 16.
  • Over the past 23 days, the trend for YMAB's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • CNS, DRUG and ORPH are the most mentioned tickers in articles about YMAB.

Latest YMAB News From Around the Web

Below are the latest news stories about Y-mAbs Therapeutics Inc that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND submission to the FDA for first SADA construct Appointed Sue Smith as Chief Commercial Officer Strong cash position with $181.6 million as of December 31, 2021, providing runway through the end of 2023 The Company will host a conference call on Friday, February 25, 2022, at 9 a.m. EST NEW YORK, Feb. 24,

Yahoo | February 24, 2022

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 25, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

GlobeNewswire | February 17, 2022

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Yahoo | February 14, 2022

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ: YMAB ) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a Pre-Biologics License Application ("pre-BLA") meeting with the U.S. Food and Drug Administration ("FDA") regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma. The Company expects to resubmit the BLA for omburtamab by the end of the first quarter 2022. A data readout from a single-center clinical study (Study 03-133) of omburtamab conducted at Memorial Sloan Kettering ("MSK")...

Benzinga | February 11, 2022

Orphazyme, Y-mAbs Therapeutics top healthcare gainers; ProQR, Senseonics lead losers pack

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%

Seeking Alpha | February 11, 2022

Y-mAbs to resubmit U.S. marketing application for neuroblastoma therapy in Q1 2022

Y-mAbs Therapeutics (YMAB) is trading ~9% higher in the pre-market on Friday after the company announced its plans to resubmit the U.S

Seeking Alpha | February 11, 2022

Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) Has Succeeded In Gaining Momentum In 2022, The Stock Is Down -56.63% YTD

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)s traded shares stood at 1.13 million during the last session, with the companys beta value hitting 1.28. At the close of trading, the stocks price was $7.03, to imply an increase of 1.59% or $0.11 in intraday trading. The YMAB shares 52-week high remains $50.70, putting it -621.19% down since that Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) Has Succeeded In Gaining Momentum In 2022, The Stock Is Down -56.63% YTD Read More »

Marketing Sentinel | February 10, 2022

YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | February 1, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5437 seconds.